|Articles|October 14, 2021
Pharmacy Clinical Pearl of the Day: Actinic Keratosis
Author(s)Saro Arakelians, PharmD
Actinic keratosis develops from years of sun exposure and usually first appears in people over 40 years of age.
Advertisement
Clinical Pearl of the Day: Actinic Keratosis
Actinic keratosis is a rough, scaly patch on the skin that develops from years of sun exposure.
Insight:
- Also known as a solar keratosis, actinic keratosis grows slowly and usually first appears in people over 40 years of age.
- The impact can be reduced by minimizing sun exposure and protecting the skin from ultraviolet rays.
- Symptoms include rough, dry, or scaly patches of skin, usually less than 1 inch in diameter; flat to slightly raised patches or bumps; a hard, wart-like surface; color variations, including pink, red, or brown skin; itching, burning, bleeding, and crusting on the skin.
- Treatment includes medicated cream or gel to remove the impacted skin, such as fluorouracil, imiquimod, or diclofenac. There are other methods also used, including freezing (cryotherapy), scraping (curettage), laser therapy, or photodynamic therapy.
- Sources:
Actinic keratosis - Symptoms and causes - Mayo Clinic actinic keratosis image - Google Search
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Related Articles
- Effectively Managing Immunizations in the Long-Term Care Setting
September 18th 2025
- Creating a Culture of Quality in Fast-Melt Tablet Development
September 18th 2025
- Advise Patients About Self-Care Measures to Treat Mild to Moderate GI Issues
September 18th 2025
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times - Pharmacy Practice News and Expert Insights
1
IMS 2025: Quadruplet Regimens Enhance Depth of Response in Multiple Myeloma
2
Updated IMWG Guidelines Spotlight MRD, Functional Imaging, and Light Chain Assays in Multiple Myeloma
3
IMS 2025: Future Directions for CAR T Therapy in Relapsed and Refractory Multiple Myeloma
4
Elranatamab Plus Daratumumab and Lenalidomide Yields Durable Responses, Manageable Safety
5